HK Stock Market Move | Jl Mag Rare-Earth (06680) rose by more than 9% at one point, as the supply and demand situation improved, and the rare earth industry is expected to see a rebound in business conditions.
Jinli Permanent Magnet (06680) rose more than 9% at one point, and as of the time of publication, it rose by 7.6% to 18.83 Hong Kong dollars, with a turnover of 97.32 million Hong Kong dollars.
Rare Earths (06680) surged by more than 9% at one point, and as of the time of this report, it has risen by 7.6%, closing at HK$18.83, with a trading volume of HK$97.3296 million.
On the news front, Guosheng pointed out that on the supply side, with the comprehensive upgrade of rare earth supply regulation in China, the bank assumes that domestic rare earth quotas will maintain a steady growth rate of 5%; overseas incremental projects are expected to gradually materialize. With the stimulus of high prices, it is expected that waste recycling supply will achieve a higher growth rate. On the demand side, the growth of demand for electric motors for new energy vehicles is expected to slow down, with Siasun Robot & Automation contributing to future incremental growth. In summary, it is estimated that the domestic supply of praseodymium neodymium oxide from 2026 to 2028 will be 11.8/12.6/13.5 thousand tons, and demand will be 12.5/13.8/15.4 thousand tons. The overall supply and demand balance of domestic praseodymium neodymium oxide is expected to remain tight, with the narrowing supply-demand gap leading to reduced marginal elasticity. Against the backdrop of continued demand growth, the price of praseodymium neodymium is expected to maintain high-level volatility.
Related Articles

QYUNS-B (02509) spent HKD 159,600 to buy back 10,000 shares on June 12th.

RONGTA TECH (09881) suggests the removal of Luo Bingxian Yongdao from the position of company auditor.

SIMCERE PHARMA (02096): SIM0689 (PD-1/VEGF dual-specific antibody) has obtained the drug clinical trial approval notice issued by the National Medical Products Administration.
QYUNS-B (02509) spent HKD 159,600 to buy back 10,000 shares on June 12th.

RONGTA TECH (09881) suggests the removal of Luo Bingxian Yongdao from the position of company auditor.

SIMCERE PHARMA (02096): SIM0689 (PD-1/VEGF dual-specific antibody) has obtained the drug clinical trial approval notice issued by the National Medical Products Administration.

RECOMMEND





